ALK-Abelló
A pharmaceutical company specializing in allergy prevention, diagnosis, and treatment.
ALK | CO
Overview
Corporate Details
- ISIN(s):
- DK0061802139
- LEI:
- 529900SGCREUZCZ7P020
- Country:
- Denmark
- Address:
- Bøge Alle 6-8, 2970 Hørsholm
- Website:
- https://www.alk.net
- Sector:
- Manufacturing
Description
ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2017-10-12 22:43 |
Meddelelse om ejerskab i ALK
|
English | PDF • 604.6 KB | ||
| 2017-09-27 09:01 | Danish | TXT • 4.2 KB | |||
| 2017-09-27 09:01 | English | TXT • 4.2 KB | |||
| 2017-09-27 09:00 |
ALKs partner, Torii, opnår godkendelse af tabletvaccine mod japansk cedertræsal…
|
English | PDF • 37.6 KB | ||
| 2017-09-27 09:00 |
ALKs partner, Torii, opnår godkendelse af tabletvaccine mod japansk cedertræsal…
|
English | PDF • 51.0 KB | ||
| 2017-09-21 19:40 | Danish | TXT • 3.9 KB | |||
| 2017-09-21 19:40 | English | TXT • 3.8 KB | |||
| 2017-09-21 19:39 |
Fransk påbud får ALK til at fremrykke investeringer i selskabets kvalitetssyste…
|
English | PDF • 33.4 KB | ||
| 2017-09-21 19:39 |
Fransk påbud får ALK til at fremrykke investeringer i selskabets kvalitetssyste…
|
English | PDF • 33.6 KB | ||
| 2017-09-14 13:15 | English | TXT • 4.4 KB | |||
| 2017-09-14 13:15 | English | PDF • 34.2 KB | |||
| 2017-09-14 13:15 |
Succesfuldt fase III-studie for ALKs tabletvaccine mod træpollenallergi
|
English | PDF • 34.2 KB | ||
| 2017-09-14 13:15 |
Succesfuldt fase III-studie for ALKs tabletvaccine mod træpollenallergi
|
English | TXT • 4.3 KB | ||
| 2017-09-04 17:21 | Danish | TXT • 14.9 KB | |||
| 2017-09-04 17:21 | English | TXT • 14.5 KB |
Automate Your Workflow. Get a real-time feed of all ALK-Abelló filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ALK-Abelló
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ALK-Abelló via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
